Pharmaceuticals

Daiichi Sankyo and Merck Expand Collaboration to Develop Delta-Like Ligand MK-6070 Targeting T Cell Attractant

bexib
By bexib 0 Min Read

Through this collaboration, the companies will jointly develop and commercialize MK-6070 worldwide, except in Japan, where Merck will retain exclusivity.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Mastercard Open Banking’s Katariina Rusznig to speak at Bank Automation Summit Europe 2024
Next Article Global stock markets rebound from sell-off, government bond yields and dollar rise Reuters – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Azzaro Group’s exciting new travel offering for 2025 combines the cultural hub of Cape Town with the unspoiled nature of the Okavango Delta
Hospitality & Tourism
Remaking history: Sarah Mather and Aquascope
Manufacturing
Christmas has arrived at Orelle – Luxury Hospitality Magazine
Hospitality & Tourism
A look inside: Allies developing a multicloud hybrid strategy
Banking